日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

A phase II study of the AKT inhibitor TAS-117 in patients with advanced solid tumors and germline PTEN mutations

一项针对晚期实体瘤和生殖系 PTEN 突变患者的 AKT 抑制剂 TAS-117 的 II 期研究

Ródon, J; Arkenau, H-T; Funchain, P; Hervieu, A; Anthony, K; Chawla, S P; Laetsch, T W; Murciano-Goroff, Y R; Singer, C F; He, Y; Mina, M; Wacheck, V; Delaloge, S

Plain language summary: an analysis of the safety of futibatinib treatment in people with different types of cancer

简明语言摘要:对不同类型癌症患者使用富巴替尼治疗的安全性分析

Meric-Bernstam, Funda; Hollebecque, Antoine; Furuse, Junji; Oh, Do-Youn; Bridgewater, John A; Anderson, Bailey; Hangai, Nanae; Wacheck, Volker; Goyal, Lipika

REZILIENT3: randomized phase III study of first-line zipalertinib plus chemotherapy in patients with EGFR exon 20 insertion-mutated NSCLC

REZILIENT3:一项随机III期研究,评估一线zipalertinib联合化疗治疗EGFR 20号外显子插入突变型非小细胞肺癌患者的疗效。

Heymach, John V; Yu, Helena A; Besse, Benjamin; Cheng, Ying; Tan, Daniel Sw; Wei, Li; Wacheck, Volker; Nishio, Makoto

Convergent MAPK pathway alterations mediate acquired resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma.

MAPK通路趋同改变介导FGFR2融合阳性胆管癌对FGFR抑制剂的获得性耐药

DiPeri Timothy P, Zhao Ming, Evans Kurt W, Varadarajan Kaushik, Moss Tyler, Scott Stephen, Kahle Michael P, Byrnes Charnel C, Chen Huiqin, Lee Sunyoung S, Halim Abdel-Baset, Hirai Hiroshi, Wacheck Volker, Kwong Lawrence N, Rodon Jordi, Javle Milind, Meric-Bernstam Funda

Safety Profile and Adverse Event Management for Futibatinib, An Irreversible FGFR1-4 Inhibitor: Pooled Safety Analysis of 469 Patients

不可逆FGFR1-4抑制剂Futibatinib的安全性概况和不良事件管理:469例患者的汇总安全性分析

Meric-Bernstam, Funda; Hollebecque, Antoine; Furuse, Junji; Oh, Do-Youn; Bridgewater, John A; Shimura, Masashi; Anderson, Bailey; Hangai, Nanae; Wacheck, Volker; Goyal, Lipika

Plain language summary of the FOENIX-CCA2 study: futibatinib for people with advanced bile duct cancer

FOENIX-CCA2 研究简明摘要:富巴替尼治疗晚期胆管癌

Goyal, Lipika; Meric-Bernstam, Funda; Hollebecque, Antoine; Valle, Juan W; Morizane, Chigusa; Karasic, Thomas B; Abrams, Thomas A; Furuse, Junji; Kelley, Robin Katie; Cassier, Philippe A; Klümpen, Heinz-Josef; Chang, Heung-Moon; Chen, Li-Tzong; Tabernero, Josep; Oh, Do-Youn; Mahipal, Amit; Moehler, Markus; Komatsu, Yoshito; Ahn, Daniel H; Epstein, Robert S; Halim, Abdel-Baset; Wacheck, Volker; He, Yaohua; Liu, Mei; Benhadji, Karim A; Bridgewater, John A

Preclinical Evaluation of the FGFR-Family Inhibitor Futibatinib for Pediatric Rhabdomyosarcoma

FGFR 家族抑制剂 Futibatinib 治疗儿童横纹肌肉瘤的临床前评估

Jerry T Wu, Adam Cheuk, Kristine Isanogle, Christina Robinson, Xiaohu Zhang, Michele Ceribelli, Erin Beck, Paul Shinn, Carleen Klumpp-Thomas, Kelli M Wilson, Crystal McKnight, Zina Itkin, Hiroshi Sotome, Hiroshi Hirai, Elizabeth Calleja, Volker Wacheck, Brad Gouker, Cody J Peer, Natalia Corvalan, Da

Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer

恩扎卢胺联合沙莫托利西布(LY3023414)或安慰剂治疗转移性去势抵抗性前列腺癌患者的Ib/II期研究

Sweeney, Christopher J; Percent, Ivor J; Babu, Sunil; Cultrera, Jennifer L; Mehlhaff, Bryan A; Goodman, Oscar B; Morris, David S; Schnadig, Ian D; Albany, Costantine; Shore, Neal D; Sieber, Paul R; Guba, Susan C; Zhang, Wei; Wacheck, Volker; Donoho, Gregory P; Szpurka, Anna M; Callies, Sophie; Lin, Boris Kin; Bendell, Johanna C

Phase 1 cohort expansion study of LY3023414, a dual PI3K/mTOR inhibitor, in patients with advanced mesothelioma

LY3023414(一种双重PI3K/mTOR抑制剂)治疗晚期间皮瘤患者的I期队列扩展研究

Zauderer, Marjorie G; Alley, Evan W; Bendell, Johanna; Capelletto, Enrica; Bauer, Todd M; Callies, Sophie; Szpurka, Anna M; Kang, Suhyun; Willard, Melinda D; Wacheck, Volker; Varghese, Anna M

Phase 1 dose-escalation study of a novel oral PI3K/mTOR dual inhibitor, LY3023414, in patients with cancer

一项针对癌症患者的新型口服PI3K/mTOR双重抑制剂LY3023414的I期剂量递增研究

Kondo, Shunsuke; Tajimi, Masaomi; Funai, Tomohiko; Inoue, Koichi; Asou, Hiroya; Ranka, Vinay Kumar; Wacheck, Volker; Doi, Toshihiko